MOLECULAR PARTNERS TO PRESENT AT THE JEFFERIES 2016 LONDON HEALTHCARE CONFERENCE Donnerstag, 10. November 2016 - 07:48
 | ||||||||||||||||
| Media Release (PDF) | ||||||||||||||||
| MOLECULAR PARTNERS TO PRESENT AT THE JEFFERIES 2016 LONDON HEALTHCARE CONFERENCE | ||||||||||||||||
Zurich-Schlieren, November 10, 2016. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that Dr. Patrick Amstutz, CEO and Andreas Emmenegger, CFO of Molecular Partners will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 3:20 PM GMT (4:20 PM CET; 10:20 AM ET). | ||||||||||||||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. DARPin® therapies are potent, specific, and versatile small proteins, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology has the potential to offer a multi-specific approach to treatment, which enables the DARPin® therapies to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. DARPin® is a registered trademark owned by Molecular Partners AG.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
|